Financial Performance - Total revenue for 2025 was RMB 173,999,859.70, a decrease of 28.19% compared to the previous year[2] - Operating profit was -RMB 53,503,630.90, with a loss increase of RMB 25,081,856.18 year-on-year[2] - Net profit attributable to shareholders was -RMB 49,883,617.84, reflecting an increase in loss of RMB 34,119,502.19 compared to the previous year[2] - Basic earnings per share were -RMB 0.90, a decline of RMB 0.62 from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 889,656,452.10, down 9.74% from the beginning of the period[2] - Equity attributable to shareholders decreased by 6.52% to RMB 849,990,809.25 compared to the beginning of the period[2] Market Conditions - The decline in revenue was attributed to intensified competition in the in vitro diagnostics industry and specific events affecting the company[5] - The company recognized impairment losses on its molecular diagnostic reagent R&D center and subsidiaries due to adverse market conditions[6] - The company anticipates limited taxable income in the future, leading to the write-off of previously recognized deferred tax assets[6] Audit and Reporting - The financial data presented is preliminary and subject to final audit in the 2025 annual report[7]

证券代码：688663 证券简称：新风光 公告编号：2026-003 新风光电子科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以新风光电子科技股份有限公司（以下简称"公司"、"新风光"）2025年年 度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 200,851.72 | 222,834.89 | -9.87 | | 营业利润 | 10,342.34 | 20,902.39 | -50.52 | | 利润总额 | 10,260.87 | 20,740.59 | -50.53 | | 归属于母公司所有者的净利润 | 9,520.88 | 18,001.76 | -47.11 | | 归属于母公司所有者的扣除非 经常性损益 ...

Financial Performance - The total operating revenue for 2025 was CNY 323.43 million, a decrease of 1.80% compared to the previous year[2] - The operating profit was CNY -104.65 million, with a loss increase of CNY 53.80 million year-on-year[5] - The total profit amounted to CNY -103.81 million, reflecting a loss increase of CNY 52.96 million compared to the previous year[5] - The net profit attributable to the parent company was CNY -84.15 million, an increase in loss of CNY 45.60 million year-on-year[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY -96.61 million, with a loss increase of CNY 43.98 million compared to the previous year[5] - The basic earnings per share were CNY -1.07, compared to CNY -0.49 in the previous year[2] - The weighted average return on net assets was -7.94%, a decrease of 4.50 percentage points year-on-year[2] Assets and Equity - Total assets at the end of the reporting period were CNY 1,308.03 million, a decrease of 5.32% from the beginning of the period[5] - Equity attributable to the parent company was CNY 1,017.81 million, down 7.54% from the beginning of the period[5] Future Plans - The company plans to enhance R&D innovation and market expansion to improve profitability and operational efficiency[10]

Financial Performance - Total revenue for 2025 reached CNY 894.12 million, a year-on-year increase of 0.68%[3] - Net profit attributable to shareholders of the parent company was CNY 21.53 million, a decrease of 66.34% compared to the previous year[3] - Basic earnings per share decreased by 65.79% to CNY 0.13[3] Assets and Equity - Total assets at the end of the reporting period were CNY 3,151.19 million, a decrease of 0.60% from the beginning of the period[4] - Shareholders' equity attributable to the parent company increased by 0.02% to CNY 2,682.62 million[4] Capital and Investments - The company implemented a capital reserve conversion, increasing its share capital by 39.85%[3] - Increased investment in key research and development and overseas markets was noted, despite rising overall expenses[6] Challenges and Strategies - The decline in net profit was primarily due to increased expenses from equity incentives and business promotion activities, as well as impairment losses[7] - The company focused on core products and localized strategies to maintain stable revenue amidst economic pressures[5] Cautionary Notes - The company warned that the financial data presented is preliminary and subject to audit, advising investors to be cautious[7]

Financial Performance - In 2025, the company achieved total operating revenue of RMB 69,782.19 million, a year-on-year increase of 33.37%[4] - The net profit attributable to the parent company was RMB 2,942.59 million, marking a turnaround from a loss in the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 4,523.49 million, also a significant improvement from the previous year[6] - The basic earnings per share improved to RMB 0.29 from a loss of RMB 0.03 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period reached RMB 119,995.29 million, an increase of 12.61% from the beginning of the period[7] - The equity attributable to the parent company was RMB 75,654.81 million, up 4.18% from the beginning of the period[7] Business Growth - The company's intelligent connected vehicle business saw growth due to increased commercial vehicle sales and market share, contributing to overall revenue growth[8] - The software platform development business maintained steady growth, providing better connectivity and management services for customers[8] Financial Challenges and Strategies - The company recorded a fair value loss of approximately RMB 2,600.00 million, impacting net profit but expected to recover in the future[9] - The company implemented cost control measures and improved project selection capabilities, enhancing profitability[10]

Financial Performance - Total revenue for 2025 was CNY 12,491.36 million, a decrease of 30.08% compared to the previous year[3] - Net profit attributable to the parent company was CNY -3,430.38 million, a reduction in loss of CNY 9,315.83 million year-on-year[5] - Basic earnings per share were CNY -0.19, an improvement from CNY -0.67 in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 376,367.96 million, a decrease of 0.69% from the beginning of the period[5] - Equity attributable to the parent company decreased by 7.92% to CNY 334,879.63 million[4] Revenue Drivers - The decline in revenue was primarily due to the implementation of centralized procurement policies, which led to lower sales prices[6] - The VAT rate for self-produced reagent products was adjusted to 13%, impacting revenue[7] Cost Management - The company implemented cost control measures, resulting in a reduction of asset impairment losses year-on-year[6] Strategic Focus - The company is focusing on product research and development to enhance market competitiveness[6] Data Integrity - There are no significant uncertainties affecting the accuracy of the financial data reported[10]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以日联科技集团股份有限公司（以下简称"公司"）2025年年度 的定期报告为准，提请投资者注意投资风险。 | | | 单位：人民币 | 万元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅度 （％） | | 营业总收入 | 107,136.88 | 73,949.59 | 44.88 | | 营业利润 | 19,321.57 | 16,087.14 | 20.11 | | 利润总额 | 19,246.48 | 15,991.84 | 20.35 | | 归属于母公司所有者的净利润 | 17,456.62 | 14,330.44 | 21.81 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | 14,508.20 | 9,617.32 | 50.85 | | 基本每股收益（元） | 1.25 | 1.02 | 22.55 | | ...

证券代码：688087 证券简称：英科再生 公告编号：2026-007 英科再生资源股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师 事务所审计，具体数据以英科再生资源股份有限公司（以下简称"公 司"）2025年年度报告中披露的数据为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 354,005.91 | 292,374.12 | 21.08 | | 营业利润 | 31,421.91 | 32,206.62 | -2.44 | | 利润总额 | 31,255.40 | 32,077.37 | -2.56 | | 归属于母公司所有者的净利 润 | 30,088.08 | 30,731.95 | -2.10 | | 归属于母公司所有者的扣除 ...

Revenue and Profitability - The total operating revenue for 2025 reached RMB 771.56 million, an increase of 14.34% compared to RMB 674.81 million in the previous year[3] - The company reported an operating loss of RMB 79.86 million, compared to a loss of RMB 67.38 million in the previous year[3] - The net profit attributable to the parent company was RMB -60.55 million, a decrease from RMB -49.53 million year-on-year[3] - The company’s net loss attributable to the parent company, excluding non-recurring gains and losses, was RMB -78.92 million, an improvement from RMB -93.60 million in the previous year[5] Assets and Equity - The total assets at the end of the reporting period were RMB 3,163.49 million, a decrease of 2.81% from RMB 3,255.09 million at the beginning of the period[5] - The equity attributable to the parent company was RMB 2,720.09 million, down 1.88% from RMB 2,772.11 million at the beginning of the period[5] Financial Performance Metrics - The weighted average return on net assets was -2.20%, a decrease of 0.42 percentage points from -1.78% in the previous year[3] - The company experienced a decline in investment income due to the previous year's gains from the transfer of equity in a joint venture[6] Cost Management - The company implemented cost control measures, resulting in a reduction of period expenses compared to the previous year[6] - The company has not reported any financial data with a change of more than 30% during the reporting period[7]

Financial Performance - In 2025, the company achieved total operating revenue of RMB 288,579.86 million, a year-on-year increase of 32.50%[4] - The net profit attributable to the parent company was RMB 13,081.59 million, a decrease of 30.97% compared to the previous year[4] - Basic earnings per share fell to RMB 0.52, a decline of 36.59% year-on-year[4] - The company’s weighted average return on equity decreased to 5.02%, down 4.65 percentage points from the previous year[4] Assets and Equity - The total assets at the end of 2025 were RMB 577,861.68 million, reflecting a year-on-year growth of 15.82%[6] - The net assets attributable to the parent company increased to RMB 264,507.68 million, up 3.14% from the previous year[6] Product Pricing and Profitability - The average price of key products, valine and myo-inositol, decreased compared to the previous year, impacting overall profitability[7] - The increase in operating expenses due to the expansion of business scale contributed to the decline in profits[8] Strategic Focus and Risks - The company continues to focus on the biotechnology sector, aiming to enhance product sales and expand market presence despite external challenges[7] - The financial data presented is preliminary and subject to final audit, highlighting the need for investors to be aware of investment risks[9]